Hybrid Au@alendronate nanoparticles as dual chemo-photothermal agent for combined cancer treatment.

A gold therapeutic nanoplatform with the same molecule used as reductant, coating and therapeutic agent has been developed in a one-pot, one-phase process using alendronate, a drug from the bisphosphonate family known for its antitumor effects. In addition, the core made of gold nanoparticles (NPs) brings thermal functionalities under irradiation within the first biological window (650-900 nm). The Au@alendronate nanoplatform thus provided a combined antitumor activity through drug delivery and photothermal therapy. Au@alendronate NPs inhibited in vitro the proliferation of prostate cancer cells (PC3) in a dose-dependent manner, with an IC value of 100 µM. Under NIR irradiation a temperature increase was observed leading to a reduction of the IC value to 1 µM, with total tumor cell death at 100 µM.